Each NSAID (non-steroidal anti-inflammatory drug) exerts its therapeutic effects by interrupting the arachidonic acid (AA) cascade, a lipid signaling pathway that generates a family of potent bioactive molecules called eicosanoids. Understanding this cascade in detail is the pharmacological foundation for predicting both the therapeutic benefits and the tissue-specific toxicities of NSAID therapy, and for understanding why cyclooxygenase (COX) isoform selectivity translates into meaningfully different clinical risk profiles. Among the two principal COX isoforms, COX-1 (cyclooxygenase-1) maintains homeostatic prostaglandin synthesis while COX-2 (cyclooxygenase-2) is the primary driver of inflammatory prostanoid production.
Membrane Phospholipids and Phospholipase A2. Arachidonic acid is a 20-carbon polyunsaturated fatty acid (a 5,8,11,14-eicosatetraenoic acid with four double bonds) that is esterified at the sn-2 position of membrane phospholipids in virtually all nucleated mammalian cells. It is not present in significant free concentrations under basal conditions; rather, it must be liberated from membrane phospholipids by the enzyme phospholipase A2 (PLA2) as the rate-limiting and stimulus-coupled step in eicosanoid synthesis. Multiple PLA2 isoforms exist, but cytosolic phospholipase A2 alpha (cPLA2 alpha), encoded by the PLA2G4A (phospholipase A2 group IVA) gene, is the primary isoform responsible for stimulus-coupled AA release in inflammatory cells. Cellular signals that activate cPLA2 include receptor-mediated rises in intracellular calcium, mitogen-activated protein kinase (MAPK) phosphorylation, and inflammatory cytokines such as interleukin-1 beta (IL-1 beta) and tumor necrosis factor alpha (TNF-alpha). Glucocorticoids suppress AA release indirectly by inducing synthesis of annexin A1 (lipocortin-1), an endogenous inhibitor of PLA2, which partly explains the superior anti-inflammatory potency of corticosteroids compared to NSAIDs, which act downstream of this step.1
The Cyclooxygenase Pathway. Once released, free arachidonic acid is metabolized by two principal enzymatic routes. The first and pharmacologically most relevant is the cyclooxygenase (COX) pathway. COX enzymes, also called prostaglandin H synthases (PGHS), catalyze a two-step reaction: first, the bis-dioxygenation of AA to prostaglandin G2 (PGG2) via the COX active site, and second, the peroxidase-mediated reduction of PGG2 to prostaglandin H2 (PGH2) via the peroxidase active site of the same bifunctional enzyme. PGH2 is an unstable intermediate that serves as the common substrate for a series of tissue-specific synthases that generate the final eicosanoid products. Prostaglandin E synthase (PGES), predominantly expressed in immune cells, the kidney, and the gastric mucosa, converts PGH2 to prostaglandin E2 (PGE2), the most pleiotropic eicosanoid and the principal mediator of inflammation-associated pain, fever, and vasodilation. Prostacyclin synthase (PGIS), expressed predominantly in vascular endothelium, converts PGH2 to prostacyclin (prostaglandin I2, PGI2), which inhibits platelet aggregation and promotes vasodilation. Thromboxane A synthase, expressed predominantly in platelets, converts PGH2 to thromboxane A2 (TXA2), which promotes platelet aggregation and vasoconstriction. The balance between endothelially produced PGI2 and platelet-derived TXA2 is a critical determinant of vascular homeostasis, and disruption of this balance is the mechanistic basis for the cardiovascular risk associated with selective COX-2 inhibitors.2
The Lipoxygenase Pathway. The second major route for AA metabolism is the lipoxygenase (LOX) pathway, which is not inhibited by NSAIDs and therefore represents a parallel inflammatory pathway that persists despite NSAID therapy. Five-lipoxygenase (5-LOX), expressed predominantly in leukocytes (neutrophils, eosinophils, mast cells, basophils), converts AA to 5-hydroperoxyeicosatetraenoic acid (5-HPETE) and then to leukotriene A4 (LTA4). LTA4 can be hydrolyzed to leukotriene B4 (LTB4), a potent chemoattractant for neutrophils and activator of neutrophil-mediated inflammation, or conjugated with glutathione by LTC4 synthase to generate the cysteinyl leukotrienes (LTC4, LTD4, LTE4), which are potent bronchoconstrictors and mediators of allergic inflammation. The clinical significance of the LOX pathway in the context of NSAID pharmacology is threefold: it explains why NSAIDs have limited efficacy in treating inflammatory conditions primarily driven by leukotriene biology (such as aspirin-exacerbated respiratory disease), it partly explains why COX inhibition alone does not abolish all inflammatory signaling, and it underpins the leukotriene shunting phenomenon in aspirin-exacerbated respiratory disease (AERD), in which COX inhibition redirects AA flux toward the LOX pathway, exacerbating bronchoconstriction.3
Physiological Roles of COX-1 Products. The downstream eicosanoids of the COX pathway serve numerous homeostatic physiological functions that are disrupted by NSAID therapy and underlie the class-wide toxicity profile. In the gastric mucosa, PGE2 and PGI2 synthesized by COX-1 (cyclooxygenase-1) stimulate mucus and bicarbonate secretion, maintain mucosal blood flow, and inhibit acid secretion by parietal cells via EP3 (prostaglandin E receptor subtype 3) receptors; loss of these cytoprotective effects is the mechanistic basis for NSAID-associated gastropathy. In the kidney, PGE2 and PGI2 synthesized in the afferent arteriole, glomerulus, and medullary interstitium maintain renal perfusion under conditions of physiological stress (volume depletion, heart failure, cirrhosis) by counteracting vasoconstriction from angiotensin II and norepinephrine; NSAID-mediated COX inhibition in this setting can precipitate acute kidney injury. In platelets, TXA2 produced by COX-1 is the primary positive-feedback signal for platelet aggregation, and irreversible COX-1 inhibition by aspirin permanently abrogates TXA2 synthesis for the platelet lifetime (8 to 10 days). In the uterus, prostaglandins stimulate myometrial contractility; suppression of prostaglandin synthesis by NSAIDs provides the rationale for their use in primary dysmenorrhea but also raises concerns about effects on uterine contractility near term. In the ductus arteriosus, PGE2 maintains vascular patency in the fetus, and NSAID-mediated COX inhibition after 20 weeks of gestation can cause premature ductal closure.1,2
PLA2 (rate-limiting step) → free arachidonic acid → COX pathway (NSAID target): PGH2 → PGE2 (inflammation, pain, fever, renal perfusion, gastric protection), PGI2 (vasodilation, anti-platelet), TXA2 (vasoconstriction, pro-platelet). LOX pathway (not inhibited by NSAIDs): LTB4 (neutrophil chemotaxis), LTC4/LTD4/LTE4 (bronchoconstriction, allergic inflammation). Glucocorticoids suppress PLA2 via annexin A1 induction, blocking both branches; NSAIDs block only COX, leaving LOX intact.
The discovery in the early 1990s that cyclooxygenase exists in two pharmacologically distinct isoforms, COX-1 (cyclooxygenase-1) and COX-2 (cyclooxygenase-2), reorganized NSAID (non-steroidal anti-inflammatory drug) pharmacology and led directly to the development of selective COX-2 inhibitors. Understanding the structural basis of isoform selectivity and the distinct expression patterns and functions of each isoform is essential for predicting the benefit-risk profile of any NSAID across the COX selectivity spectrum.
COX-1: Constitutive Isoform. COX-1, encoded by the PTGS1 (PTGS1: prostaglandin-endoperoxide synthase 1) gene on chromosome 9, is constitutively expressed in most mammalian tissues including the gastric mucosa, kidney, platelets, and vascular endothelium. It is the housekeeping isoform responsible for maintaining basal prostaglandin levels that subserve physiological functions: gastric cytoprotection, renal perfusion maintenance, platelet thromboxane A2 (TXA2) synthesis, and baseline vascular tone regulation. COX-1 expression is not significantly altered by inflammatory stimuli, cytokines, or glucocorticoids; its transcriptional activity is controlled by constitutive promoter elements including specificity protein 1 (Sp1) and activating protein 2 (AP-2) binding sites but not nuclear factor kappa B (NF-kappaB)-responsive elements. Because COX-1 is the source of tissue-protective prostaglandins, its inhibition by non-selective NSAIDs accounts for much of the class-wide toxicity profile, particularly gastrointestinal (GI) and renal adverse effects.1
COX-2: Inducible Isoform. COX-2, encoded by the PTGS2 (PTGS2: prostaglandin-endoperoxide synthase 2) gene on chromosome 1, is an immediate-early gene whose expression is rapidly induced (within two to four hours) by inflammatory stimuli including lipopolysaccharide (LPS), interleukin-1 beta (IL-1 beta), tumor necrosis factor alpha (TNF-alpha), epidermal growth factor (EGF), and mechanical shear stress. Its promoter contains NF-kappaB, cyclic adenosine monophosphate (cAMP) response element (CRE), and nuclear factor for interleukin-6 (NF-IL6) binding sites that account for its transcriptional responsiveness to inflammatory signals. COX-2 is the dominant source of prostaglandin E2 (PGE2) and prostacyclin (PGI2) in inflamed tissues, the pyrogenic prostaglandins in the hypothalamus, and the prostanoids that sensitize peripheral nociceptors. The conceptual rationale for selective COX-2 inhibition was that blocking the inducible, inflammation-specific isoform would produce anti-inflammatory, analgesic, and antipyretic effects while sparing COX-1-dependent cytoprotective prostaglandins, thereby reducing GI toxicity. This rationale was partially validated (COX-2 selective agents do cause less GI mucosal injury) but failed to account for the cardiovascular consequences of selectively sparing COX-2 in vascular endothelium.2,4
Structural Basis of Selectivity. COX-1 and COX-2 share approximately 60% amino acid sequence identity and nearly identical active site architecture, but a critical difference at position 523 determines selectivity: COX-1 has an isoleucine residue at this position (Ile-523), while COX-2 has the smaller valine (Val-523). This single amino acid substitution creates a side pocket off the main COX-2 active site channel that is accessible in COX-2 but physically occluded in COX-1. Selective COX-2 inhibitors (the coxibs, including celecoxib, rofecoxib, and valdecoxib) are bulky molecules designed to fit into this COX-2-specific side pocket, conferring high selectivity ratios (50-fold to greater than 1000-fold COX-2 over COX-1 inhibition in cell-based assays). Non-selective NSAIDs bind the main active site channel and inhibit both isoforms without accessing the side pocket. The mechanism of inhibition for most NSAIDs (including ibuprofen, naproxen, and celecoxib) is competitive and reversible; aspirin is unique in forming an irreversible covalent bond with a serine residue (Ser-530 in COX-1, Ser-516 in COX-2) via acetylation.4
COX-2 Constitutive Expression and the Cardiovascular Risk. The original hypothesis that COX-2 is exclusively inducible and inflammatory is incorrect; COX-2 is constitutively expressed in several tissues with important physiological functions. Vascular endothelium constitutively expresses COX-2 as the source of PGI2, which inhibits platelet aggregation and promotes vasodilation. The kidney constitutively expresses COX-2 in the macula densa and medullary interstitium, where it regulates sodium reabsorption and renin release. The brain expresses COX-2 constitutively in cortical neurons, where it participates in synaptic signaling. Selective COX-2 inhibition in vascular endothelium reduces endothelial PGI2 production while leaving platelet TXA2 (a COX-1 product) fully intact, creating a prothrombotic and vasoconstrictive imbalance. This mechanism, confirmed in the VIGOR (Vioxx Gastrointestinal Outcomes Research) and APPROVe (Adenomatous Polyp Prevention on Vioxx) trials with rofecoxib and subsequently found with all selective COX-2 inhibitors, explains the class-wide cardiovascular risk of the coxibs and ultimately led to the withdrawal of rofecoxib from the market in 2004.5
The COX Selectivity Spectrum. NSAID COX selectivity exists on a continuous spectrum rather than as a binary classification. At one extreme are the highly selective COX-2 inhibitors (celecoxib, and the withdrawn rofecoxib and valdecoxib). In the intermediate zone are the preferentially COX-2 selective agents: meloxicam demonstrates approximately 10-fold COX-2 selectivity at therapeutic doses and etodolac shows COX-2 preference in cell-based assays. Diclofenac, though structurally classified as a non-selective NSAID, achieves COX-2 preferential inhibition in vivo at therapeutic plasma concentrations, which may account for its somewhat greater GI tolerability compared to ibuprofen but also for its associated cardiovascular signal. At the non-selective end are ibuprofen, naproxen, indomethacin, ketorolac, and piroxicam, which inhibit COX-1 and COX-2 at similar concentrations. Among non-selective agents, naproxen has the most favorable cardiovascular profile, potentially because its long half-life allows sustained platelet COX-1 inhibition that partly mimics the antiplatelet effect of low-dose aspirin; this observation underpins the recommendation that naproxen is the preferred NSAID in patients with or at high risk for cardiovascular disease who require an NSAID for musculoskeletal pain.5
Benefit of COX-2 selectivity: reduced gastric mucosal injury compared to non-selective NSAIDs (but not elimination of GI risk). Cost: prothrombotic and vasoconstrictive state from endothelial PGI2 suppression without platelet TXA2 suppression. Net clinical principle: the cardiovascular risk of NSAIDs increases with COX-2 selectivity and dose. The renal risk is class-wide regardless of COX selectivity. Use the lowest effective dose of the least COX-2 selective agent tolerated for the shortest duration necessary.
Despite diverse chemical structures, each NSAID (non-steroidal anti-inflammatory drug) shares several core pharmacokinetic features that arise from common physicochemical properties: weak organic acids (pKa 3 to 5), highly lipophilic, and extensively protein-bound. These properties govern absorption, distribution, metabolism, and excretion (ADME) in ways that have direct clinical consequences for dosing interval selection, drug interaction risk, and management in special populations.
Absorption. All orally administered NSAIDs are well absorbed from the gastrointestinal (GI) tract, with oral bioavailability generally exceeding 80% for most agents. Being weak acids, NSAIDs are partially ionized at gastric pH, which promotes passive absorption across the gastric epithelium, but the majority of absorption occurs in the small intestine due to its large surface area. Food slows but does not substantially reduce absorption and is routinely recommended to minimize local GI irritation. Enteric-coated formulations (available for aspirin, diclofenac, and naproxen) delay absorption by preventing dissolution until the intestine but do not reduce systemic GI toxicity, because NSAID-mediated gastropathy occurs through the systemic suppression of mucosal COX-1 (cyclooxygenase-1)-derived prostaglandins, not solely through local mucosal contact. Extended-release formulations (naproxen sodium controlled-release, diclofenac extended-release, meloxicam) reduce peak plasma concentrations, allowing once-daily dosing and potentially reducing peak-related adverse effects. Ketorolac is the only NSAID available for intramuscular (IM) and intravenous (IV) administration in addition to oral dosing, providing parenteral access for short-term acute pain management in settings where oral dosing is not feasible.6
Protein Binding and Distribution. NSAIDs are among the most highly protein-bound drugs in clinical use, with free fractions typically below 1 to 5% of total plasma concentration. Albumin is the primary binding protein, with binding occurring predominantly at Sudlow site I and site II. This extreme protein binding has several pharmacological consequences. The volume of distribution (Vd) is small (0.1 to 0.2 L/kg for most agents), meaning NSAIDs remain predominantly in the vascular compartment and do not distribute extensively into peripheral tissues despite achieving high concentrations at sites of inflammation, where the local low pH and increased vascular permeability promote drug accumulation. NSAIDs compete with each other and with other highly protein-bound drugs (warfarin, methotrexate, lithium) for albumin binding sites, creating the potential for displacement interactions that transiently increase free drug concentrations of the displaced agent. In patients with hypoalbuminemia (hepatic cirrhosis, nephrotic syndrome, malnutrition), total plasma NSAID concentrations may underestimate the pharmacologically active free fraction, necessitating dose caution. NSAIDs penetrate synovial fluid slowly but achieve concentrations comparable to plasma over several hours, providing effective intra-articular exposure after oral dosing despite their low Vd.6
Hepatic Metabolism. The NSAIDs are predominantly metabolized by hepatic cytochrome P450 (CYP) enzymes, with CYP2C9 (cytochrome P450 2C9) being the predominant isoform for the majority of clinically important agents including ibuprofen, naproxen, celecoxib, diclofenac, meloxicam, and piroxicam. CYP2C9 catalyzes hydroxylation and carboxylation reactions that generate pharmacologically inactive metabolites that are subsequently conjugated (primarily via glucuronidation by UDP-glucuronosyltransferases (UDP: uridine diphosphate; UGTs)) and excreted renally. Indomethacin is notable for undergoing extensive enterohepatic recirculation, which prolongs its effective half-life and increases GI mucosal exposure. Ketorolac is metabolized by hydroxylation and glucuronidation without significant CYP involvement. Sulindac is a prodrug that requires hepatic sulfide reduction to generate the pharmacologically active sulfide metabolite; it is then oxidized back to the inactive sulfone by hepatic flavin monooxygenase (FMO), creating a metabolic cycling that extends its duration of action. CYP2C9 polymorphisms (particularly the poor metabolizer alleles CYP2C9*2 and CYP2C9*3) can reduce NSAID clearance by 50 to 75% in homozygous poor metabolizers, increasing toxicity risk at standard doses; however, routine CYP2C9 genotyping before NSAID prescribing is not standard clinical practice.7
Renal Excretion and Half-Life. After hepatic metabolism and conjugation, NSAID metabolites are excreted primarily in the urine via glomerular filtration and tubular secretion. A small fraction of unchanged drug may also be renally excreted. Because NSAID clearance depends primarily on hepatic metabolism rather than renal filtration, dose adjustment based on renal function is not required for standard NSAID dosing in patients with mild to moderate chronic kidney disease (CKD). This pharmacokinetic point must be distinguished from the nephrotoxic effects of NSAIDs, which worsen renal function in susceptible patients regardless of their baseline glomerular filtration rate (GFR). Half-life varies enormously across the class and is the primary determinant of dosing interval: ibuprofen has a short half-life of 1.8 to 2 hours, requiring dosing every 4 to 6 hours for sustained analgesia; naproxen has a half-life of 12 to 17 hours allowing twice-daily or once-daily dosing; piroxicam has a half-life of 30 to 86 hours permitting once-daily dosing but creating a slow offset when adverse effects occur.6
Meloxicam has a half-life of approximately 20 hours for once-daily dosing; celecoxib has a half-life of 8 to 12 hours dosed twice daily. The long half-life of piroxicam and to a lesser degree naproxen has been associated with a disproportionately high risk of serious GI complications in epidemiological studies, possibly reflecting sustained COX-1 inhibition without offset periods between doses. The short half-life of ibuprofen, by contrast, creates intervals of COX-1 recovery between doses that may reduce cumulative mucosal injury at lower analgesic doses compared to agents with sustained COX inhibition throughout the dosing interval.5
| Agent | Half-Life | COX Selectivity | Primary Metabolism | Dosing Interval |
|---|---|---|---|---|
| Ibuprofen | 1.8–2 h | Non-selective | CYP2C9 | q4–6h |
| Naproxen | 12–17 h | Non-selective | CYP2C9 | q12h or q24h |
| Indomethacin | 4.5–6 h | Non-selective | CYP2C9, enterohepatic | q8–12h |
| Ketorolac | 5–6 h | Non-selective | Glucuronidation | q6h (max 5 days) |
| Diclofenac | 1–2 h | COX-2 preferential | CYP2C9, CYP3A4 | q8–12h |
| Meloxicam | ~20 h | COX-2 preferential | CYP2C9, CYP3A4 | q24h |
| Celecoxib | 8–12 h | Selective COX-2 | CYP2C9 | q12–24h |
| Piroxicam | 30–86 h | Non-selective | CYP2C9 | q24h |
CYP2C9 inhibitors (fluconazole, amiodarone, fluvoxamine, voriconazole) reduce NSAID clearance and increase plasma concentrations and toxicity risk. CYP2C9 inducers (rifampin, carbamazepine, St. John's wort) increase NSAID clearance, potentially reducing efficacy. CYP2C9 poor metabolizer genotypes (*2/*2, *3/*3) can double or triple plasma NSAID concentrations at standard doses. Celecoxib is a moderate CYP2D6 inhibitor and can increase plasma concentrations of CYP2D6 substrates (metoprolol, codeine, tricyclic antidepressants) when co-administered.
Aspirin (acetylsalicylic acid) occupies a unique position among the NSAIDs (non-steroidal anti-inflammatory drugs) by virtue of its irreversible mechanism of action, its markedly dose-dependent pharmacological effects, and its dual role as both an anti-inflammatory agent and an antiplatelet drug. Its pharmacology illustrates how a single mechanism of covalent cyclooxygenase (COX) inhibition produces qualitatively different clinical effects depending on dose, dosing frequency, and the regenerative capacity of the target cell. The following discussion covers aspirin absorption, distribution, metabolism, and excretion (ADME), followed by its dose-response pharmacology.
Mechanism: Irreversible COX Acetylation. Aspirin is unique among NSAIDs in that it inhibits COX irreversibly by transferring its acetyl group to the hydroxyl group of serine-530 in COX-1 (cyclooxygenase-1) and serine-516 in COX-2 (cyclooxygenase-2), forming a covalent ester bond that permanently inactivates the enzyme. This acetylation physically blocks the substrate channel of COX-1 and modifies the substrate channel of COX-2 to produce a novel enzymatic activity: the acetylated COX-2 converts arachidonic acid (AA) to 15(R)-HETE and then to 15-epi-lipoxin A4 (aspirin-triggered lipoxin), which has anti-inflammatory and pro-resolving properties distinct from the usual prostanoid products. The irreversibility of COX-1 inhibition by aspirin is the pharmacological basis for its antiplatelet effect: platelets lack nuclei and cannot synthesize new COX protein, so aspirin-mediated COX-1 acetylation permanently abolishes thromboxane A2 (TXA2) synthesis for the entire lifespan of that platelet (approximately 8 to 10 days). Because approximately 10% of the platelet pool is renewed each day, the antiplatelet effect of a single aspirin dose wanes over approximately 8 to 10 days as new COX-1-containing platelets enter circulation. This regeneration kinetics explains why aspirin must be taken daily to maintain continuous antiplatelet effect.8
Aspirin ADME. Aspirin is rapidly absorbed from the stomach and small intestine; its oral bioavailability is approximately 50 to 60% for plain aspirin tablets because it undergoes pre-systemic hydrolysis by esterases in the gut wall and portal circulation to salicylate, the primary circulating species after ingestion. Aspirin itself has a very short plasma half-life of approximately 15 to 20 minutes, rapidly hydrolyzed to salicylate in plasma and tissues. Because acetylation of platelet COX-1 occurs in the portal circulation even during first-pass absorption, this brief systemic exposure is sufficient to produce durable antiplatelet effects. Salicylate, the hydrolysis product, has a much longer half-life that is dose-dependent due to saturable hepatic metabolism. At low antiplatelet doses (75 to 325 mg), salicylate is eliminated primarily by conjugation with glycine (forming salicyluric acid) and glucuronide (salicyl glucuronide and phenolic glucuronide), with a half-life of approximately 2 to 3 hours. At higher analgesic and anti-inflammatory doses (1,000 to 6,000 mg/day), these conjugation pathways saturate and the elimination half-life extends to 6 to 12 hours, with a greater fraction undergoing renal excretion of unchanged salicylate.9
Urinary pH profoundly affects salicylate elimination: alkalinization of urine (as occurs with sodium bicarbonate, acetazolamide, or high-dose antacid therapy) increases ionization of salicylate in the tubular lumen and reduces tubular reabsorption, markedly accelerating excretion, a principle exploited in salicylate toxicity management. At toxic doses, zero-order kinetics dominate and small dose increments produce disproportionate plasma concentration increases. Protein binding of salicylate is also dose-dependent; it saturates at anti-inflammatory doses, increasing the free fraction and amplifying toxicity risk nonlinearly with dose escalation.9
Dose-Dependent Pharmacology. The pharmacological effects of aspirin are strikingly dose-dependent. At low doses (75 to 325 mg/day), aspirin selectively inhibits platelet COX-1 with minimal effect on vascular endothelial COX-2, because platelets are exposed to high drug concentrations in the portal circulation during first-pass absorption before aspirin is hydrolyzed to salicylate, while endothelial cells, which can regenerate COX-2, recover their prostacyclin synthetic capacity between daily doses. This selective platelet effect at low doses is the pharmacological rationale for antiplatelet therapy. At intermediate doses (300 to 1,000 mg per dose), aspirin provides analgesia and antipyresis through COX inhibition in peripheral tissues and the hypothalamus. At high doses (3 to 6 grams/day), aspirin achieves sustained COX-2 inhibition in inflamed tissues sufficient for anti-inflammatory effect, though these doses are rarely used today due to the high incidence of gastrointestinal (GI) toxicity and the availability of more tolerable alternatives. An additional phenomenon important at high salicylate doses is the uncoupling of oxidative phosphorylation in mitochondria at toxic concentrations, contributing to the metabolic acidosis and hyperthermia seen in salicylate toxicity. Aspirin also inhibits platelet COX-2-derived prostacyclin (PGI2) at very low doses, but this effect is pharmacologically minor compared to the dominant TXA2 suppression at standard antiplatelet doses.8,9
75–325 mg/day: antiplatelet (irreversible platelet COX-1 acetylation, TXA2 suppression for 8–10 days, selective because endothelium regenerates COX). 300–1,000 mg per dose: analgesic and antipyretic (peripheral and hypothalamic COX inhibition). 3,000–6,000 mg/day: anti-inflammatory (sustained high-dose COX inhibition, rarely used today). Toxic doses: uncoupling of oxidative phosphorylation, tinnitus, hyperventilation, respiratory alkalosis followed by metabolic acidosis. Key clinical point: enteric coating does NOT reduce GI risk at antiplatelet doses and delays onset of effect in acute coronary syndrome.
While each NSAID (non-steroidal anti-inflammatory drug) shares the core mechanism of cyclooxygenase (COX) inhibition, clinically meaningful differences in pharmacokinetics, COX selectivity, tissue distribution, and drug interaction potential distinguish the individual agents and guide agent selection for specific clinical situations. Each ARB (angiotensin receptor blocker) and other antihypertensive co-medication interaction is covered in the drug interaction subsection below.
Ibuprofen. Ibuprofen is a propionic acid derivative that is a racemic mixture of the R(-) and S(+) enantiomers; only the S(+) enantiomer inhibits COX, but the R(-) enantiomer undergoes chiral inversion to S(+) in vivo in humans, so the racemic mixture is effectively fully active. It has the shortest half-life of the commonly used NSAIDs (1.8 to 2 hours) and requires dosing every 4 to 6 hours for sustained analgesic effect. Ibuprofen reversibly occupies the COX-1 (cyclooxygenase-1) active site and can interfere with aspirin's access to Ser-530 for acetylation if dosed before aspirin; this pharmacodynamic interaction means that ibuprofen should be taken at least 30 minutes after or more than 8 hours before aspirin in patients requiring both agents, to avoid attenuation of aspirin's antiplatelet effect. This interaction is clinically important in patients on aspirin for secondary cardiovascular prevention who also require ibuprofen for pain. Naproxen, by contrast, does not appear to interfere with aspirin's antiplatelet effect to the same degree and is the preferred non-selective NSAID in this setting. Ibuprofen is the most widely used over-the-counter NSAID and has a well-established safety profile at low doses (200 to 400 mg per dose), though its gastrointestinal (GI) and renal risks are dose-dependent and become clinically meaningful at anti-inflammatory doses (400 to 800 mg three to four times daily).10
Naproxen. Naproxen is a propionic acid derivative marketed as the active S(+) enantiomer (unlike ibuprofen, no chiral inversion is needed). Its long half-life (12 to 17 hours) allows twice-daily and in some formulations once-daily dosing, improving adherence. Naproxen has the most favorable cardiovascular risk profile among non-selective NSAIDs, based on epidemiological data and meta-analyses consistently showing lower rates of major adverse cardiovascular events compared to ibuprofen, diclofenac, and celecoxib; the proposed mechanism involves sustained COX-1-mediated antiplatelet activity from its long half-life, producing a partial aspirin-like effect. This property makes naproxen the preferred NSAID choice in patients with cardiovascular risk factors when an NSAID cannot be avoided. Its GI risk profile is intermediate; at equivalent anti-inflammatory doses it carries lower GI risk than indomethacin or piroxicam but higher than celecoxib.5
Indomethacin. Indomethacin is an indoleacetic acid derivative and one of the most potent non-selective COX inhibitors available. It is particularly effective for crystal-induced arthropathy (acute gout and pseudogout) and ankylosing spondylitis. It also has a unique clinical application in closing a hemodynamically significant patent ductus arteriosus (PDA) in preterm neonates by inhibiting prostaglandin-mediated ductal patency; this indication uses intravenous indomethacin in neonatal intensive care settings. Indomethacin undergoes extensive enterohepatic recirculation via glucuronide hydrolysis in the intestine, which prolongs its effective duration of action but also increases intestinal mucosal exposure and GI toxicity. It has the highest rate of central nervous system (CNS) adverse effects of any NSAID, including headache (paradoxically, given its use for cluster headache prophylaxis), cognitive changes, and exacerbation of psychiatric illness, limiting its long-term use. At full anti-inflammatory doses it carries higher GI and renal toxicity risk than most other NSAIDs and is not recommended for routine use in elderly patients.6
Ketorolac. Ketorolac is a pyrrolizine carboxylic acid derivative distinguished by its availability for parenteral (IM and IV) administration, making it the NSAID of choice for short-term acute pain management in settings where oral dosing is not feasible (postoperative pain, renal colic, acute musculoskeletal injury). It is a highly potent non-selective COX inhibitor with analgesic potency comparable to moderate opioid doses (30 mg IM ketorolac approximately equivalent to 10 mg IM morphine in some acute pain models), allowing opioid-sparing in postoperative pain management. However, its potent and non-selective COX inhibition also confers significant GI and renal toxicity risk that increases sharply with duration of use. Current labeling restricts use to a maximum of 5 days total (oral plus parenteral combined), and the parenteral formulation is limited to a maximum of 60 mg on the first day for elderly patients or those under 50 kg and 120 mg per day for younger patients. Patients with pre-existing renal impairment, elderly patients, and those who are volume-depleted are at substantially elevated risk for ketorolac-associated acute kidney injury.6
Celecoxib. Celecoxib is the only selective COX-2 (cyclooxygenase-2) inhibitor currently available in the United States following the market withdrawal of rofecoxib (2004) and valdecoxib (2005). It is a diaryl heterocycle (sulfonamide-substituted pyrazole) with approximately 375-fold selectivity for COX-2 over COX-1 in whole-blood assays at therapeutic concentrations. Its oral bioavailability is approximately 40%, and it is metabolized primarily by CYP2C9 (cytochrome P450 2C9) with a minor contribution from CYP3A4 (cytochrome P450 3A4). Celecoxib is a moderate inhibitor of CYP2D6 (cytochrome P450 2D6), which is clinically relevant when co-prescribed with CYP2D6 substrates including metoprolol (increased metoprolol concentrations and heart rate slowing), codeine (reduced analgesic effect from impaired conversion to morphine), and tricyclic antidepressants. Celecoxib causes significantly less gastric and duodenal mucosal injury than non-selective NSAIDs at equivalent anti-inflammatory doses; the Celecoxib Long-Term Arthritis Safety Study (CLASS) demonstrated fewer symptomatic ulcers and ulcer complications compared to ibuprofen and diclofenac, though the benefit was attenuated in patients taking concomitant low-dose aspirin. Its cardiovascular risk is considered intermediate among NSAIDs, greater than naproxen but potentially lower than rofecoxib; the PRECISION (Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen or Naproxen) trial found celecoxib non-inferior to ibuprofen and naproxen for cardiovascular risk in a high-cardiovascular-risk population, providing important comparative data.4,5
Diclofenac. Diclofenac is a phenylacetic acid derivative with COX-2 preferential inhibition in vivo despite its structural classification as a non-selective NSAID. It is metabolized by CYP2C9 (primary) and CYP3A4, with glucuronide and sulfate conjugates excreted in bile and urine. Diclofenac has a distinct hepatotoxicity signal: it causes transaminase elevations in up to 15% of patients at standard doses (75 to 150 mg/day), with clinically significant hepatotoxicity (greater than three times the upper limit of normal) in approximately 1 to 3% of patients on prolonged therapy; the mechanism involves cytochrome P450 (CYP)-mediated formation of a reactive acyl glucuronide metabolite. Liver function tests should be monitored during prolonged diclofenac therapy, and the drug should be discontinued if transaminase levels exceed three times the upper limit of normal. Diclofenac also carries a higher cardiovascular risk signal than naproxen in epidemiological studies, comparable to selective COX-2 inhibitors, which limits its use in patients with cardiovascular disease despite its relatively favorable GI profile among the non-selective agents.5
Pharmacodynamic Drug Interactions Across the Class. Beyond the CYP2C9-mediated pharmacokinetic interactions discussed earlier, NSAIDs participate in several clinically important pharmacodynamic drug interactions. NSAIDs combined with anticoagulants (warfarin, direct oral anticoagulants) increase bleeding risk through additive anticoagulant effects plus impaired platelet function; this combination sharply increases the risk of serious GI bleeding and should be used only when no alternative exists, with careful monitoring. NSAIDs combined with antihypertensive agents including angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and diuretics reduce antihypertensive efficacy by blocking prostaglandin-dependent vasodilation and increasing sodium retention; the combination of an ACE inhibitor or ARB, a diuretic, and an NSAID constitutes the "triple whammy" associated with a substantially elevated risk of acute kidney injury (AKI).6
NSAIDs increase lithium plasma concentrations by reducing renal prostaglandin synthesis and thereby reducing renal lithium clearance; lithium toxicity can occur, and lithium levels should be monitored when NSAIDs are initiated or discontinued. NSAIDs impair the renal excretion of methotrexate (MTX) at high MTX doses (greater than 15 mg/week), raising the risk of MTX toxicity; this interaction is most concerning in oncology settings where high-dose MTX is used. Selective serotonin reuptake inhibitors (SSRIs) combined with NSAIDs increase the risk of GI bleeding beyond that of either agent alone, because SSRIs deplete platelet serotonin and impair platelet activation while NSAIDs suppress COX-1-dependent thromboxane A2 (TXA2).11
Ibuprofen + aspirin: ibuprofen competitively blocks aspirin acetylation of COX-1 — take aspirin first or separate by 8 hours. NSAIDs + warfarin/DOACs: additive bleeding risk, especially GI. NSAIDs + ACE inhibitor/ARB + diuretic: triple whammy AKI — avoid this combination. NSAIDs + lithium: reduced renal lithium clearance — monitor lithium levels. NSAIDs + high-dose methotrexate (>15 mg/week): reduced MTX excretion — significant toxicity risk. NSAIDs + SSRIs: additive GI bleeding risk. Celecoxib + CYP2D6 substrates (metoprolol, codeine, tricyclics): increased substrate exposure.
Translating NSAID (non-steroidal anti-inflammatory drug) pharmacology into rational prescribing requires matching the pharmacokinetic and pharmacodynamic profile of the available agents to the clinical indication, the duration of intended therapy, and the patient's individual risk factors for gastrointestinal (GI), cardiovascular, and renal adverse effects. The following framework integrates the preceding pharmacological content into actionable prescribing principles.
Pain and Inflammation. NSAIDs are effective for mild to moderate nociceptive and inflammatory pain and are first-line therapy for musculoskeletal pain, osteoarthritis (OA), rheumatoid arthritis (RA), ankylosing spondylitis (AS), acute gout, and post-traumatic or postoperative pain. For acute musculoskeletal pain and mild to moderate postoperative pain, ibuprofen 400 to 600 mg every 6 to 8 hours or naproxen 500 mg twice daily provide effective analgesia with predictable onset. For acute gout, indomethacin 50 mg three times daily or naproxen 500 mg twice daily are the most evidence-supported NSAID regimens; indomethacin is preferred when very rapid onset is desired (it achieves high synovial fluid concentrations rapidly due to its lipophilicity), while naproxen is preferred in elderly patients or those with cardiovascular or renal risk factors. For chronic inflammatory arthritis (RA, AS, psoriatic arthritis), NSAIDs provide symptomatic relief but do not modify the underlying disease course; they are used as adjuncts to disease-modifying antirheumatic drugs (DMARDs) rather than as primary therapy in these conditions. For OA, NSAIDs remain the most effective oral analgesic class, but given the chronic nature of the disease and long-term toxicity risks, topical diclofenac (1.5% solution or 1% gel) should be considered as first-line for hand and knee OA in patients with GI or cardiovascular risk factors, as topical application provides local efficacy with minimal systemic exposure.12
Fever and Dysmenorrhea. NSAIDs are highly effective antipyretics through central inhibition of prostaglandin E2 (PGE2) synthesis in the hypothalamus. Ibuprofen and aspirin are the most widely used; both are superior to acetaminophen (paracetamol) for fever reduction in adults, though acetaminophen is preferred in patients with GI intolerance, coagulopathy, or aspirin-exacerbated respiratory disease. For primary dysmenorrhea, NSAIDs are the treatment of choice, reducing prostaglandin-mediated uterine contractility, ischemia, and pain. Mefenamic acid (a fenamate NSAID), naproxen, and ibuprofen have the strongest evidence base for dysmenorrhea; initiation 1 to 2 days before expected onset of menstruation and continuation through the first 2 to 3 days provides superior relief compared to as-needed dosing. NSAIDs should be avoided during pregnancy, particularly after 20 weeks of gestation, due to the risk of premature closure of the ductus arteriosus and oligohydramnios from reduced fetal renal prostaglandin synthesis; the US Food and Drug Administration (FDA) issued a warning in 2020 strengthening this restriction.1
Agent Selection by Risk Profile. Selecting among NSAIDs requires systematic assessment of four domains of patient risk: GI risk (prior peptic ulcer, GI bleeding, H. pylori status, age above 65, high-dose or dual NSAID use, concomitant anticoagulant or corticosteroid use), cardiovascular risk (established coronary artery disease, cerebrovascular disease, peripheral arterial disease, Framingham risk score above 10%), renal risk (baseline estimated glomerular filtration rate (GFR) below 60 mL/min/1.73m2, heart failure, cirrhosis, volume depletion), and hepatic risk (cirrhosis, active hepatitis, transaminase elevation).5 Patients with low GI and low cardiovascular risk can use any NSAID at the lowest effective dose for the shortest duration. Patients with high GI risk but low cardiovascular risk should receive a selective COX-2 (cyclooxygenase-2) inhibitor (celecoxib) or a non-selective NSAID plus a proton pump inhibitor (PPI). Patients with low GI risk but high cardiovascular risk should receive naproxen, as it has the most favorable cardiovascular profile, with PPI co-therapy if needed. Patients with both high GI and high cardiovascular risk should avoid NSAIDs if possible; if unavoidable, naproxen plus PPI co-therapy is preferred, with close monitoring. All NSAIDs should be avoided or used with extreme caution in patients with an estimated GFR below 30 mL/min/1.73m2, decompensated heart failure, or active peptic ulcer disease.12
Mechanism: COX inhibition reduces prostaglandin and TXA2 synthesis; LOX pathway unaffected. Aspirin is unique: irreversible COX-1 acetylation, dose-dependent pharmacology (antiplatelet 75–325 mg; analgesic/antipyretic 300–1,000 mg/dose; anti-inflammatory 3,000–6,000 mg/day). COX-2 selectivity reduces GI mucosal injury but increases cardiovascular risk via PGI2/TXA2 imbalance. Naproxen has the most favorable cardiovascular profile. Key interactions: ibuprofen blocks aspirin antiplatelet effect; all NSAIDs raise lithium levels and attenuate antihypertensives; triple whammy (NSAID + ACE inhibitor/ARB + diuretic) causes AKI. CYP2C9 metabolizes most NSAIDs; CYP2C9 inhibitors (fluconazole, amiodarone) increase NSAID toxicity.
Ricciotti E, FitzGerald GA. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol. 2011;31(5):986-1000.
doi:10.1161/ATVBAHA.110.207449Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol. 1998;38:97-120.
doi:10.1146/annurev.pharmtox.38.1.97Peters-Golden M, Henderson WR Jr. Leukotrienes. N Engl J Med. 2007;357(18):1841-1854.
doi:10.1056/NEJMra071371Patrono C, Patrignani P, Garcia Rodriguez LA. Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. J Clin Invest. 2001;108(1):7-13.
doi:10.1172/JCI13418Bhala N, Emberson J, Merhi A, et al; Coxib and traditional NSAID Trialists' (CNT) Collaboration. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382(9894):769-779.
doi:10.1016/S0140-6736(13)60900-9Brune K, Patrignani P. New insights into the use of currently available non-steroidal anti-inflammatory drugs. J Pain Res. 2015;8:105-118.
doi:10.2147/JPR.S75160Kirchheiner J, Brockmöller J. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther. 2005;77(1):1-16.
doi:10.1016/j.clpt.2004.08.009Patrono C. Aspirin as an antiplatelet drug. N Engl J Med. 1994;330(18):1287-1294.
doi:10.1056/NEJM199405053301808Needs CJ, Brooks PM. Clinical pharmacokinetics of the salicylates. Clin Pharmacokinet. 1985;10(2):164-177.
doi:10.2165/00003088-198510020-00004Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001;345(25):1809-1817.
doi:10.1056/NEJMoa003199Lanas A, Scheiman J. Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment. Curr Med Res Opin. 2007;23(1):163-173.
doi:10.1185/030079907X162656Hochberg MC, Altman RD, April KT, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken). 2012;64(4):465-474.
doi:10.1002/acr.21596